Swiss CDMOs and CROs ride a new wave of growth amid surge in global demand

A surge of consolidation, rising appetite for specialized manufacturing and a shift toward decentralized trials is reshaping Switzerland’s life sciences landscape. From peptide producers to organoid CROs, service providers are scaling and diversifying as global sponsors turn to Swiss hubs for talent, innovation and regulatory strength.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top